EGFR Inhibition Abrogates Leiomyosarcoma Cell Chemoresistance through Inactivation of Survival Pathways and Impairment of CSC Potential

PLoS ONE

Volumn 7, Issue 10, 2012, Pages

  Sette, Giovanni ^a   Salvati, Valentina ^a   Memeo, Lorenzo ^b   Fecchi, Katia ^a   Colarossi, Cristina ^b   Di Matteo, Paola ^a   Signore, Michele ^a   Biffoni, Mauro ^a   D'Andrea, Vito ^c   de Antoni, Enrico ^c   Canzonieri, Vincenzo ^d   de Maria, Ruggero ^e   Eramo, Adriana ^a  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^b Mediterranean Institute of Oncology   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^e REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DACARBAZINE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; ETOPOSIDE; GEFITINIB; GEMCITABINE; TEMOZOLOMIDE; VINCRISTINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER STEM CELL; CANCER SURVIVAL; CARCINOGENICITY; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL DIFFERENTIATION; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXICITY; IN VITRO STUDY; IN VIVO STUDY; LEIOMYOSARCOMA; MESENCHYMAL STEM CELL; MOUSE; NONHUMAN; PHENOTYPE; SOFT TISSUE SARCOMA; XENOGRAFT;

ANIMALS; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SURVIVAL; DRUG RESISTANCE, NEOPLASM; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; HUMANS; LEIOMYOSARCOMA; MICE; NEOPLASM GRADING; NEOPLASTIC STEM CELLS; PHENOTYPE; PHOSPHOPROTEINS; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; VINCRISTINE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84867306379     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0046891     Document Type: Article

References (42)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, et al. (2008) Cancer statistics, 2008. CA Cancer J Clin 58: 71-96.
2. Mackall CL, Meltzer PS, Helman LJ, (2002) Focus on sarcomas. Cancer Cell 2: 175-178.
3. Osuna D, de Alava E, (2009) Molecular pathology of sarcomas. Rev Recent Clin Trials 4: 12-26.
4. Rubio R, Garcia-Castro J, Gutierrez-Aranda I, Paramio J, Santos M, et al. (2010) Deficiency in p53 but not retinoblastoma induces the transformation of mesenchymal stem cells in vitro and initiates leiomyosarcoma in vivo. Cancer Res 70: 4185-4194.
5. Rodriguez R, Rubio R, Menendez P, (2012) Modeling sarcomagenesis using multipotent mesenchymal stem cells. Cell Res 22: 62-77.
6. Weitz J, Antonescu CR, Brennan MF, (2003) Localized extremity soft tissue sarcoma: improved knowledge with unchanged survival over time. J Clin Oncol 21: 2719-2725.
7. Coindre JM, Terrier P, Guillou L, Le Doussal V, Collin F, et al. (2001) Predictive value of grade for metastasis development in the main histologic types of adult soft tissue sarcomas: a study of 1240 patients from the French Federation of Cancer Centers Sarcoma Group. Cancer 91: 1914-1926.
8. Penel N, Italiano A, Isambert N, Bompas E, Bousquet G, et al. (2009) Factors affecting the outcome of patients with metastatic leiomyosarcoma treated with doxorubicin-containing chemotherapy. Ann Oncol 21(6): 1361-1365.
9. Van Glabbeke M, van Oosterom AT, Oosterhuis JW, Mouridsen H, Crowther D, et al. (1999) Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: an analysis of 2,185 patients treated with anthracycline-containing first-line regimens-a European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study. J Clin Oncol 17: 150-157.
10. Blay JY, van Glabbeke M, Verweij J, van Oosterom AT, Le Cesne A, et al. (2003) Advanced soft-tissue sarcoma: a disease that is potentially curable for a subset of patients treated with chemotherapy. Eur J Cancer 39: 64-69.
11. Krikelis D, Judson I, (2010) Role of chemotherapy in the management of soft tissue sarcomas. Expert Rev Anticancer Ther 10: 249-260.
12. Hensley ML, Maki R, Venkatraman E, Geller G, Lovegren M, et al. (2002) Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial. J Clin Oncol 20: 2824-2831.
13. Talbot SM, Keohan ML, Hesdorffer M, Orrico R, Bagiella E, et al. (2003) A phase II trial of temozolomide in patients with unresectable or metastatic soft tissue sarcoma. Cancer 98: 1942-1946.
14. Garcia-Carbonero R, Supko JG, Manola J, Seiden MV, Harmon D, et al. (2004) Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy. J Clin Oncol 22: 1480-1490.
15. Hernando E, Charytonowicz E, Dudas ME, Menendez S, Matushansky I, et al. (2007) The AKT-mTOR pathway plays a critical role in the development of leiomyosarcomas. Nat Med 13: 748-753.
16. Oda Y, Saito T, Tateishi N, Ohishi Y, Tamiya S, et al. (2005) ATP-binding cassette superfamily transporter gene expression in human soft tissue sarcomas. Int J Cancer 114: 854-862.
17. Visvader JE, Lindeman GJ, (2008) Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer 8: 755-768.
18. Eramo A, Lotti F, Sette G, Pilozzi E, Biffoni M, et al. (2008) Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death Differ 15: 504-514.
19. Eramo A, Ricci-Vitiani L, Zeuner A, Pallini R, Lotti F, et al. (2006) Chemotherapy resistance of glioblastoma stem cells. Cell Death Differ 13: 1238-1241.
20. O'Brien CA, Pollett A, Gallinger S, Dick JE, (2007) A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 445: 106-110.
21. Ricci-Vitiani L, Lombardi DG, Pilozzi E, Biffoni M, Todaro M, et al. (2007) Identification and expansion of human colon-cancer-initiating cells. Nature 445: 111-115.
22. Zhou BB, Zhang H, Damelin M, Geles KG, Grindley JC, et al. (2009) Tumour-initiating cells: challenges and opportunities for anticancer drug discovery. Nat Rev Drug Discov 8: 806-823.
23. Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, et al. (2004) Identification of human brain tumour initiating cells. Nature 432: 396-401.
24. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF, (2003) Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A 100: 3983-3988.
25. Levings PP, McGarry SV, Currie TP, Nickerson DM, McClellan S, et al. (2009) Expression of an exogenous human Oct-4 promoter identifies tumor-initiating cells in osteosarcoma. Cancer Res 69: 5648-5655.
26. Gibbs CP, Kukekov VG, Reith JD, Tchigrinova O, Suslov ON, et al. (2005) Stem-like cells in bone sarcomas: implications for tumorigenesis. Neoplasia 7: 967-976.
27. Tirino V, Desiderio V, d'Aquino R, De Francesco F, Pirozzi G, et al. (2008) Detection and characterization of CD133+ cancer stem cells in human solid tumours. PLoS One 3: e3469.
28. Wu C, Wei Q, Utomo V, Nadesan P, Whetstone H, et al. (2007) Side population cells isolated from mesenchymal neoplasms have tumor initiating potential. Cancer Res 67: 8216-8222.
29. Honoki K, (2010) Do stem-like cells play a role in drug resistance of sarcomas? Expert Rev Anticancer Ther 10: 261-270.
30. Pierobon M, Calvert V, Belluco C, Garaci E, Deng J, et al. (2009) Multiplexed Cell Signaling Analysis of Metastatic and Nonmetastatic Colorectal Cancer Reveals COX2-EGFR Signaling Activation as a Potential Prognostic Pathway Biomarker. Clin Colorectal Cancer 8: 110-117.
31. Sorrentino A, Ferracin M, Castelli G, Biffoni M, Tomaselli G, et al. (2008) Isolation and characterization of CD146+ multipotent mesenchymal stromal cells. Exp Hematol 36: 1035-1046.
32. Mohseny AB, Hogendoorn PC, (2011) Mesenchymal Tumors: When Stem Cells Go Mad. Stem Cells. 29(3): 397-403.
33. Valtieri M, Sorrentino A, (2008) The mesenchymal stromal cell contribution to homeostasis. J Cell Physiol 217: 296-300.
34. Halfon S, Abramov N, Grinblat B, Ginis I, (2011) Markers distinguishing mesenchymal stem cells from fibroblasts are downregulated with passaging. Stem Cells Dev 20: 53-66.
35. Romanov YA, Svintsitskaya VA, Smirnov VN, (2003) Searching for alternative sources of postnatal human mesenchymal stem cells: candidate MSC-like cells from umbilical cord. Stem Cells 21: 105-110.
36. Thomadaki H, Floros KV, Scorilas A, (2009) Molecular response of HL-60 cells to mitotic inhibitors vincristine and taxol visualized with apoptosis-related gene expressions, including the new member BCL2L12. Ann N Y Acad Sci 1171: 276-283.
37. Noguchi K, Kawahara H, Kaji A, Katayama K, Mitsuhashi J, et al. (2009) Substrate-dependent bidirectional modulation of P-glycoprotein-mediated drug resistance by erlotinib. Cancer Sci 100: 1701-1707.
38. Carcaboso AM, Elmeliegy MA, Shen J, Juel SJ, Zhang ZM, et al. (2010) Tyrosine kinase inhibitor gefitinib enhances topotecan penetration of gliomas. Cancer Res 70: 4499-4508.
39. Bartucci M, Svensson S, Romania P, Dattilo R, Patrizii M, et al. (2012) Therapeutic targeting of Chk1 in NSCLC stem cells during chemotherapy. Cell Death Differ 19: 768-778.
40. Francescangeli F, Patrizii M, Signore M, Federici G, Di Franco S, et al. (2012) Proliferation State and Polo-like Kinase1 Dependence of Tumorigenic Colon Cancer Cells. Stem Cells 30(9): 1819-1830.
41. Ren W, Korchin B, Zhu QS, Wei C, Dicker A, et al. (2008) Epidermal growth factor receptor blockade in combination with conventional chemotherapy inhibits soft tissue sarcoma cell growth in vitro and in vivo. Clin Cancer Res 14: 2785-2795.
42. Ren W, Korchin B, Lahat G, Wei C, Bolshakov S, et al. (2008) Combined vascular endothelial growth factor receptor/epidermal growth factor receptor blockade with chemotherapy for treatment of local, uterine, and metastatic soft tissue sarcoma. Clin Cancer Res 14: 5466-5475.